Continued Monitoring: Regular follow-ups with your healthcare provider to assess tolerance and progress
Meanwhile, Novo Nordisk has submitted its oral semaglutide tablet (oral Wegovy) for weight-management indication, reporting ~15% weight loss in a ~64-68-week study
They were bad people for whom the solution was for them to become good, says William Stauffer, executive director of Pennsylvania Recovery Organizations Alliance, who has written about the history of recovery movements
In contrast, SGLT2 inhibitor monotherapy is not likely to provide sufficient weight loss for treatment of obesity per se, but could have other benefits in obese patients with co-morbidities such as atherosclerotic cardiovascular disease, heart failure, or renal disease
Patients should inspect their pen before each injection
However, their remarkable potential is not without obstacles, one of which is the mode of administration by subcutaneous injection